Market Access NICE and the controversy over a ‘clinically distinct disease... Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.
Market Access Transformative trends with real-world data from early access... The complex and changing needs of patients with life-threatening conditions has led many health authorities to introduce early access programmes.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
